Search results for Johnson & Johnson Innovative Medicine

<![CDATA[Johnson & Johnson’s Experience Navigating The Commissioner’s National Priority Voucher Program]]>

Johnson & Johnson Joins TrumpRX

Three name-brand diabetes drugs and a blood thinner are now available at a discount on the government platform and J&J’s own website.

J&J gets naming rights to the Johnson & Johnson Exchange at the New Jersey Innovation Hub, Powered by Portal Inn...

Portal Innovations, in partnership with the New Brunswick Development Corporation (DEVCO) and HELIX, announced May 19 that Johnson & Johnson received naming rights to the Johns...

Johnson & Johnson: Success In Multiple Myeloma Underpins $25B In Growth By 2030

Johnson & Johnson Launches Initiative To Support Access To Liquid Biopsy Testing For Non-Small Cell Lung Cancer In T...

Johnson & Johnson has announced a new initiative in the United Arab Emirates aimed at supporting access to liquid biopsy testing for patients diagnosed with metastatic non-smal...

<![CDATA[Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson &...

J&J leans on Tremfya, cancer drugs to overcome Stelara losses

A growing multiple myeloma franchise helped the pharmaceutical giant top Wall Street’s expectations and surpass $15 billion in first-quarter drug sales.

Johnson & Johnson teams up with Viz.ai on hematoma detection

Johnson & Johnson is working with artificial intelligence (AI) disease detection and care coordination platform Viz.ai to boost its neurovascular offerings.

INLEXZOâ„¢ (gemcitabine intravesical system) Assigned Permanent Billing Code, Supporting Access for Patients with Certai...

Johnson & Johnson (NYSE:JNJ) today announced the permanent Healthcare Common Procedure Coding System (HCPCS) J-code for INLEXZOв„ў (gemcitabine intravesical system) is now in e...

Two Paths to Growth: Johnson & Johnson vs AbbVie

Cerenovus Division

Cerenovus Division Anonymous (not verified) Sun, 05/03/2026 - 14:19 field_thread_url https://cafepharma.com/boards/threads/cerenovus-division.685354/...

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

JNJ (NYSE: JNJ) to release Q1 earnings before bell on April 14. Analysts expect $2.67/share & $23.6B revenue. FDA approves TECNIS PureSee lens. Latest Ratings for JNJ Date...

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Johnson & Johnson announced the launch of VARIPULSE Pro in Europe following CE Mark approval, further advancing its pulsed field ablation (PFA) portfolio. This new pulse sequen...

Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript

Laser Photonics Expands into Precision Medical Device Manufacturing with Custom Laser Drilling System Order from Johnson...

$250K Development System Order from Johnson & Johnson Represents Entry into Medical Device Manufacturing; Successful Validation Could Enable Broader Deployment Across Manufactu...

<![CDATA[ Implications of Tecvayli Plus Darzalex Faspro Demonstrating 83% Reduction in Disease Progression or Death.]...

Cerenovus Division

Cerenovus Division Anonymous (not verified) Fri, 04/24/2026 - 11:14 field_thread_url https://cafepharma.com/boards/threads/cerenovus-division.685354/...

Investing in health is key to Vietnam's next phase of growth: Johnson & Johnson Innovative Medicine

Every US$1 invested in healthcare can generate up to US$4 in economic returns by creating a healthier and more productive workforce, according to Upendra Patkie, General Manager of...

Johnson & Johnson (JNJ) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

<![CDATA[Pharma Finance Roundup: Platform Innovation Drives Biotech Investment Across Oncology and Immunology]]>

Johnson & Johnson Q2 Earnings Review: Why You Should Be Buying The Stock Today

J&J sees AI halving the time to generate drug development leads

3rd Circ. Upholds J&J Injunction Bid Loss In Biosimilar Fight

The Third Circuit on Tuesday ruled that a Johnson & Johnson subsidiary couldn't justify its bid for an order blocking Samsung Bioepis from paving the way for a Cigna unit to la...

<![CDATA[Model Examples]]>